STRATEGIC FOCUS
- Cancer vaccines are the next generation therapies in oncology
- Vaccentis <AIPI> technology platform - All Individualized Precision Immunotherapy tumour vaccine technology is advantageous
- Lead candidate VCC-001 builds on strong clinical data including a Phase III and real world data from a compassionate use program
- Regulatory approval for VCC-001 planned by 2029
- Manufacturing capabilities for VCC-001 production for planned clinical trials and compassionate use program guaranteed by established partner
- Vaccentis <AIPI> technology platform has significant potential for multiple other tumour indications
